<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Insulin treatment is considered to be the final option for patients with progressive type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated, whether reconverting type 2 patients from insulin treatment to oral treatment using <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> is possible without deterioration of blood <z:chebi fb="105" ids="17234">glucose</z:chebi> control </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The PioSwitch study was a prospective, open label, proof of concept study </plain></SENT>
<SENT sid="3" pm="."><plain>Thiazolidinedione-na√Øve patients with residual beta-cell function were switched from an existing insulin therapy to treatment with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and <z:chebi fb="0" ids="5383">glimepiride</z:chebi> for 6 months </plain></SENT>
<SENT sid="4" pm="."><plain>Efficacy was assessed by laboratory parameters and scores for evaluation of metabolic control, beta-cell function, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and cardiovascular risk </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In total, 98 patients [66 men, 32 women, age (mean +/- s.d.): 59 +/- 9 years; disease duration: 5.6 +/- 3.6 years; <z:chebi fb="0" ids="35143">Hemoglobin</z:chebi> A1c (HbA1c): 6.9 +/- 0.8%; body mass index (BMI): 33.9 +/- 5.2 kg/m(2), initial daily insulin therapy dose: 0.36 +/- 0.3 U/kg body weight] out of 117 screened patients were treated </plain></SENT>
<SENT sid="6" pm="."><plain>During the observation period, 23 patients were prematurely terminated because of an increase in HbA1c from baseline &gt; 0.5% or other reasons </plain></SENT>
<SENT sid="7" pm="."><plain>In 75 patients (76%), no deterioration of <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism occurred and additional improvements were seen in the majority of the observation parameters [baseline vs. endpoint; HbA1c: 6.79 +/- 0.74%/6.66 +/- 0.69% (p &lt; 0.05), <z:chebi fb="105" ids="17234">glucose</z:chebi>: 6.4 +/- 1.5/5.2 +/- 1.4 mmol/l (p &lt; 0.001), adiponectin: 7 +/- 3 mg/l/17 +/- 8 mg/l (p &lt; 0.001), C-<z:chebi fb="7" ids="16670">peptide</z:chebi>: 987 +/- 493/1756 +/- 789 (p &lt; 0.001), sensitivity index derived from the intravenous <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test (SI(ivGTT)): 1.21 +/- 0.85/1.49 +/- 0.95 (p &lt; 0.05), hsCRP: 3.3 +/- 2.4/2.6 +/- 2.4 mg/l (p &lt; 0.01), macrophage chemo-attractant protein 1 (MCP1): 487 +/- 246/382 +/- 295 ng/l (p &lt; 0.05)] </plain></SENT>
<SENT sid="8" pm="."><plain>BMI increased from 33.8 +/- 5.1 to 34.4 +/- 5.3 kg/m(2) (p &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The switch from insulin therapy resulting in a moderately HbA1c level, to oral treatment with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> was successful in a majority of patients with sufficient residual beta-cell function </plain></SENT>
<SENT sid="10" pm="."><plain>It allows a simple and less expensive therapy with a better cardiovascular risk marker profile </plain></SENT>
</text></document>